Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer
Go back to Guardant Health COSMOS Study Published in Clinical Cancer Research Validates Utility of Guardant Reveal™ Liquid Biopsy Test for Predicting Recurrence in Colorectal Cancer| Textainer Group Holdings limited (NASDAQ: GH) | Delayed: 128.58 -3.2 (2.43%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $131.78 | 52 Week High | $5.84 | |||
| Open | $131.16 | 52 Week Low | $5.49 | |||
| Day High | $132.07 | P/E | N/A | |||
| Day Low | $125.12 | EPS | $0.00 | |||
| Volume | 959,839 | |||||
